LRMR · Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States
Biotechnology
Healthcare

Market Cap

310.6M

52 Wk Range

$1.92 - $6.42

Previous Close

$2.99

Open

$2.95

Volume

1,405,031

Day Range

$2.93 - $3.35

Enterprise Value

190M

Cash

128.7M

Avg Qtr Burn

-31.19M

Insider Ownership

1.26%

Institutional Own.

N/A

Qtr Updated

Sep 30th 2026